XL413 (BMS-863233)

Co-developed with Bristol-Myers Squibb Company.

Development Status

A Phase 1 clinical trial evaluating the safety XL413 is ongoing.

Description

XL413 is potent, selective, and orally available small molecule inhibitor of the serine-threonine kinase Cdc7. The function of Cdc7 is required for cellular DNA synthesis to proceed, and its activity is often upregulated in cancer cells. Studies suggest that Cdc7 plays a role in regulation of cell cycle checkpoint control, and protects tumor cells from apoptotic cell death during replication stress. Therefore, inhibition of Cdc7 may have utility in the treatment of a wide variety of cancers, either as a single agent or in combination with DNA damaging agents.

XL413 is being co-developed with Bristol-Myers Squibb Company (BMS), and BMS has primary responsibility for the development and commercialization of the compound. We exercised our option under our collaboration agreement with BMS to co-develop and co-commercialize XL413 in the United States.

Information on Clinical Trials

Information about ongoing clinical trials of Exelixis' investigational product candidates is available at ClinicalTrials.gov, a service of the U.S. National Institutes of Health. General information about clinical trials and issues related to participating in clinical trials also is available at ClinicalTrials.gov.